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Abbreviations
6-OHDA 6-hydroxydopamine
AD Alzheimer’s disease
ALS amyotrophic lateral sclerosis
AMPA alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid
AP-1 activator protein-1
AR-JP autosomal recessive juvenile parkinsonism
AT axon terminál
ATP adenosine triphosphate
C l,-3,-5
Ca2+
complement-1, -3, -5 
calcium
CNS central nervous system
COX-2 cyclooxygenase-2
CSF cerebrospinal fluid
Cu/Zn SÓD Cu/Zn superoxide dismutase
DA dopamine
DAB-3,3' diaminobenzidine tetrahydrochloride-3,3'
DLBD diffuse Lewy body disease
EAAs excitatory amino acids
EAAT2 excytarory amino acid transporter
EC endothelial cell
FALS familial ALS
FPD familial Parkinson disease
GFAP glial fibrillary acidic protein
ICAM-1 intercellular adhesion molecule-1
IFN-y
IgG
IL
interferon-gamma 
immunoglobulin G 
interleukin
iNOS inducible nitric oxide synthase
ÍP
KA
intraperitoneal
kainate
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LMN lower motor neuron
Mit mitochondrion
MN motor neuron
MPTP 1 -methyl-4-phenyl-l ,2,3,6-tetrahydropyridine
My myelin
NAD+ nicotinamide adenine dinucleotide
NF neurofilament
NF-kB nuclear transcriptional factor kappa B
NMDA N-methyl-D-aspartate
nNOS neuronal nitric oxide synthase
N nucleus
NO nitric oxide
ONOO' peroxynitrite
PARP poly-ADP-(ribose)-polymerase
p a r p -ir PARP immunoreactivity
PBS phosphate-buffered saline
PD Parkinson disease
RER rough endoplasmic reticulum
ROS reactive oxygen species
SALS sporadic ALS
SN substantia nigra
s v synaptic vesicles
TGF transforming growth factor
TNF-R1 TNF-a receptor
TNF-a tumor necrosis factor alpha
UCH-L1 ubiquitin carboxy terminál hydrolase-Ll
UMN upper motor neuron
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1. Introduction
Parkinson disease (PD) and amyotrophic lateral sclerosis (ALS) are devastating 
neurodegenerative diseases which ultimately lead to death. While the clinical course 
and the signs of the diseases are totally different, they have a common feature; the 
selective neuronal death. In ALS, there is a loss of upper motor neurons (UMNs - 
cortical) and lower motor neurons (LMNs - spinal, bulbar, and pontine), whereas in PD 
the selective death of DA-ergic neurons in the substantia nigra (SN) is the main feature. 
Several lines of experimental evidence have proved the combined role of genetic 
defects, environmental factors, oxidative stress, immune/inflammatory reactions, 
excitatory mechanisms, and overactivation of the DNA repair enzyme the poly-ADP- 
(ribose)-polymerase (PARP) in selective neuron degeneration. It is still unknown which 
one of the proposed mechanisms is the initiator of the selective neuronal death.
1.1. Parkinson disease
PD is a neurodegenerative movement disorder characterized by hypokinesia, rigidity, 
resting tremor and postural instability. The pathological hallmarks of the disease are 
Lewy body inclusions in the DA-ergic cells and a selective and progressive loss of the 
DA-ergic cells in the SN. The forms of PD include the relatively rare, early-onset 
familial PD (FPD) and a late-onset, sporadic PD form. Specific mutations have been 
identified in at least five separate genes and linked to different forms of FPD. The 
discovery of alpha-synuclein, ubiquitin C-terminal hydrolase, parkin, tau and DJ1 
(PARK7) mutations and analysis of the biochemical and molecular properties of these 
gene products point to the critical role of protein aggregation in the degeneration of the 
DA-ergic neurons of the SN. Evén in sporadic PD the Lewy bodies contain somé of 
these gene products, and particularly abundant fibrillar alpha-synuclein. However, in 
sporadic PD, the causes of the cell demise remain unknown. The neurodegeneration 
may result írom a decreased activity of the proteasome. A defect in the detoxifícation of 
reactive oxygen species (ROS), or an energy failure caused by inhibition of the 
mitochondrial respiratory chain at the level of complex I, or caused by overactivation of 
the DNA repair enzyme, PARP, are other hypotheses that are described in the literature. 
Finally, activated microglial cells around the degenerating DA-ergic neurons and 
complex immune-inflammatory processes might alsó intervene in the mechanism of
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degeneration by perpetuating or amplifying, and (according to somé authors) even 
initiating the primary neuronal insult.
b
It is still unclear which of the presumed factors and what extent are responsible fór the 
degeneration of the DA-ergic neurons. There are several possibilities: genetic factors, 
environmental, endogenous risk factors, a mitochondrial dysfunction, or oxidative 
damage summarized bellow.
Environm ental risk factors
Pesticides/herbicides, mitochondrial inhibitors 
(rotenone, paraquat), MPTP
G enetic factors
Mutations in a-synuclein, parkin, ubiquitin 
hydrolase
Endogenous risk factors
Abnormal DA metabolism  
Mitochondrial dysfunction 
Activation o f  inflammatory cells
Oxidation/Nitration
\
Decline o f  glutathione levels, 
reducing antioxidant capacity
Inhibition o f  mitochondrial 
respiration:
Decline in oxidative 
phosphorylation and ATP
a-S ynuclein/protein 
aggregation: 
inclusions, Lewy bodies
\
C ell death
\
PD
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1.1.1. The genetic factors
Genetic analyses have identified three causative genes: PARKI (alpha-synuclein), 
PARK2 iparkin), and PARK7 (DJ-1). Additionally, mutations in several other genes 
have been implicated in familial PD. Deletions or point mutations in the gene fór parkin 
cause autosomal recessive juvenile parkinsonism (AR-JP). Moreover, it is known that 
the role of parkin protein in the brain is to break down misfolded proteins via the 
proteosomal pathway as an ubiquitin-protein ligásé. It is hypothesized that loss of this 
function results in the toxic accumulation of its target proteins. Disturbance of protein 
degradation by the ubiquitin-proteasome system may have a critical role in 
neurodegeneration. Although alpha-synuclein mutations are inffequent, alpha-synuclein 
accumulates in Lewy bodies, and alpha-synuclein fíbrils impair the 26S proteasome 
function. Ubiquitin carboxy-terminal hydrolase-Ll (UCH-L1) is alsó an abundant 
deubiquitinylating enzyme, and its mutation is linked to PARK5. Another PD causative 
gene, DJ-1 functions as a sensor fór oxidative stress (1). Most of the genes found to be 
mutated in PD have played a role in the ubiquitin-proteasome system.
There is much evidence of decreased enzymatic activity in the affected parts of the 
brains of patients with AR-JP. Mutations in parkin lead to an accumulation of 
nonubiquitinated proteins in DA neurons. The impairment of the ubiquitin-proteasome 
system and the resulting toxicity of poorly degraded proteins could be the cause of PD 
in these individuals. DJ-1 is similarly involved in the ubiquitin-proteasome pathway fór 
two reasons. First, mutations leading to misfolded DJ-1 might overload the ubiquitin- 
proteasome system and decrease its effectiveness. Second, DJ-1 is thought to be 
involved in oxidative damage, which is known to increase the rate of aggregation of 
alpha-synuclein. Alpha-synuclein, however, is nőt limited strictly to DA-ergic neurons, 
and therefore its accumulation can nőt fully explain the specificity seen in the disease.
In the non-genetic forms of PD, there is alsó well-known DNA damage caused in the 
DA-ergic neurons by toxins, oxidative stress. The DNA breaks activate its repair 
enzyme PARP. The latter alsó has an important role in the pathomechanism of sporadic 
PD.
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1.1.2. Environmental risk factors
The theory that exposure to somé toxins may contribute to nigrostriatal neuronal death 
was a result of the accidental intoxication of drug users by l-methyl-4-phenyl-l,2,3,6- 
tetrahydropyridine (MPTP), which was a contaminant of Street drugs. People 
intoxicated with MPTP presented with a sudden onset of all the symtoms of PD, 
although with less tremor and more cognitive impairment, drooling and balance 
difficulty. The pathologic hallmarks characteristic of PD, namely the Lewy bodies, were 
nőt seen in experimental PD induced in primates by MPTP. Several Chemical products 
used in herbicides and pesticides are similar structurally to MPTP, including paraquat, 
diquat and rotenone. In view of this fact, somé animal models were developed fór the 
selective nigrostriatal damage, such as neurotoxicity induced by rotenone, paraquat or 
MPTP, which emphasised that environmental agents may conduce to the 
neurodegenerative process in PD. There is a link between MPTP toxicity and PARP 
activation because MPTP potently activates PARP exclusively in vulnerable DA- 
containing neurons of the SN. MPTP elicits a növel pattem of poly-(ADP-ribosyl)-ation 
of nuclear proteins that completely depends on neuronally derived nitric oxide (NO). 
NO, DNA damage and PARP activation play critical roles in MPTP-induced 
parkinsonism and suggest that inhibitors of PARP may be of protective benefit in the 
treatment of PD (2).
1.1.3. Oxidative stress
Oxidative stress has been proposed as one of several pathogenic hypotheses in PD. 
Oxidative stress is a unifying factor in the current theories of PD pathogenesis, because 
it links genetic and potential environmental factors (mitochondrial inhibitors such as 
rotenone, paraquat and MPTP) to the initiation of the disease process.
Oxidative stress is intimately linked to other components of the degenerative process, 
such as a mitochondrial dysfunction, excitotoxicity, toxicity by NO and inflammation. 
MPTP administration has been shown to increase levels of superoxide both 
intracellularly, via the inhibition of mitochondrial respiration, and extracellularly, via 
the activation of microglia. Microglial activation is regulated in part by nuclear 
transcription factor (NF-kB). The nuclear enzyme PARP-1 enhances NF-kB binding to 
DNA. PARP-1 activity is necessary fór its fiinction as a coactivator of NF-kB.
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Pharmacological PARP inhibitors have been shown to block the effect of PARP-1 on 
NF-kB binding to DNA. Superoxide and NO production by neuronal NO synthase 
(nNOS) or by microglial inducible NO synthase (iNOS) alsó contributes to MPTP 
neurotoxocity.
There is increasing evidence that mitochondrial function impairment, oxidative damage 
and inflammation are factors contributing to neurodegeneration. A defect in the 
detoxification of ROS or an energy failure caused by inhibition of the mitochondrial 
respiratory chain, at the complex I level, are other hypotheses that are frequently 
mentioned. Finally, activated microglial cells around the degenerating DA-ergic 
neurons may alsó intervene in the mechanism of degeneration by perpetuating or even 
ampliíying the primary neuronal insult. A mitochondrial dysfunction can result in the 
excessive production of ROS, triggering the apoptotic death of DA-ergic cells in PD.
1.1.4. Excitotoxicity
The main excitatory amino acids (EAAs) are L-glutamate and L-aspartate. The 
excitatory responses in the Central nervous system (CNS) are mediated by four different 
receptor subtypes. Three of these receptors are coupled to ion channels: the N-methyl- 
D-aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA), 
and kainate (KA) receptors. The fourth receptor subtype is linked to the phosphoinositol 
Cascade and is known as the metabotrophic receptor. Studies on the molecular 
mechanism of neuronal injury caused by excessive stimulation of glutamate receptors 
showed that glutamate may be toxic to neurons in several ways. The NMDA receptor is 
coupled with a voltage-gated calcium (Ca2+) channel and its stimulation causes elevated 
intracellular calcium Ca2+ levels. The activation of non-NMDA receptors (AMPA and 
KA) results in an influx of Na , followed by an influx of Ca . Destabilization of the 
intracellular Ca2+ level activates protein kinases, phospholipases, proteases and NOS, 
impairs the mitochondrial function, generates free radicals and initiates apoptosis.
In the normál brain, the concentrations of EAAs within the synaptic eleft are maintained 
at subtoxic levels, with rapid uptake and inactivation by both neurons and glia. Nigral 
DA-ergic neurons possess glutamate receptors (3, 4) and they degenerate if exposed to 
an excitotoxic impact of glutamate (6, 7). The antagonism of excitotoxicity has been 
regarded as potential therapy in PD. Antagonists of ionotropic glutamate receptors, and
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especially antagonists of the NMDA receptor and its modulatory glycine site, improve 
PD symptoms, bút severe side-effects associated with their use during chronic therapy 
limit their efficacy as potential drugs.
High levels of glutamate can be lethal fór neurons via secondary excitotoxicity. 
Mitochondrial impairment alsó disrupts cellular Ca homoeostasis. Facilitation of the 
NMDA-receptor function leads to a further mitochondrial dysfunction. This largely 
occurs due to Ca entering the neurons through NMDA receptors with 'privileged' 
access to mitochondria. An elevated intracellular Ca2+ level causes free-radical 
production and mitochondrial depolarization. Glutamate in the presence of an impaired 
cellular energy metabolism acts as a neurotoxin. In this way, glutamate may participate 
in the pathogenesis of PD (8, 9).
1.1.5. The role of iron in neurodegeneration
írón is believed to be a key contributor to PD pathology by inducing the aggregation of 
alpha-synuclein and by generating oxidative stress. Histopathological, biochemical and 
brain imaging techniques, such as magnetic resonance imaging and transcranial 
sonography, have revealed a consistent increase of the brain iron level in the SN in PD. 
A series of recent studies suggest that iron regulatory proteins coordinate both cellular 
iron levels and energy metabolism, which are both disrupted in PD. Iron has alsó 
recently been implicated in the promotion of alpha-synuclein aggregation, either 
directly or by increasing levels of oxidative stress, suggesting an important role fór it in 
Lewy body formádon, another important hallmark of the disease (10).
1.1.6. Immune/inflammatory theories
The presence of activated microglia in the SN pars compacta in patients with PD has 
prompted investigations of the role of immune/inflammatory proeesses in 
neurodegenerative disorders, including PD. The SN pars compacta contains icreased 
levels of cytokines, such as tumor necrosis factor alpha (TNF-a), interleukin (IL)-lbeta, 
IL-2, IL-4, IL-6 and transforming growth factor (TGF)-alpha, TGF-betal and TGF- 
beta2. In tűm, the levels of neurotrophins, such as brain-derived neurotrophic factor and 
nerve growth factor, are decreased in the nigrostriatal DA regions and in the ventricular 
and lumbar cerebrospinal fluid (CSF) of PD patients. Furthermore, the levels of the
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TNF-a receptor RÍ (TNF-R1), bcl-2, soluble Fás (sFas), and the activities of caspase-1 
and caspase-3 are alsó elevated in the nigrostriatal DA regions in PD (11). Increased 
levels of proinflammatory cytokines, cytokine receptors, caspase activities, and reduced 
levels of neurotrophins in the nigrostriatal region in PD patients, and in its animal 
models (MPTP- and 6-hydroxy-DA-produced PD animals) suggest the increased 
immuné reactivity and programmed cell death (apoptosis) of neuronal cells, alterations 
in the function of the astrocytes and activation of the microglia. These data indicate a 
proapoptotic environment in the SN in PD which may induce the increased vulnerability 
of neuronal cells. The DA-ergic neurons may lack the protection given by the 
astrocytes. Another possibility is that the microglia cells themselves could contribute to 
neurodegeneration through an inflammatory process. It is believed that activated 
microglia exerts cytotoxic effects in the brain through two very different and yet 
complementary processes (12). First, they can act as phagocytes, which involve direct 
cell-to-cell contact. Second, they are capable of releasing a large variety of potentially 
noxious substances, such as iNOS, IL-ip, IL-2, IL-6, IL-10, cyclooxygenase-2 (COX- 
2), TNF-a, interferon (IFN-y). (13-15) and glutamate (16). Altematively, superoxide 
released by activated microglia can react with NO in the extracellular space to form the 
highly reactive tissue-damaging species peroxynitrite (ONOO ), which can cross the cell 
membráné and injure neurons. Therefore, by eontributing to peroxynitrite formation, 
microglia-derived superoxide may participate in the death of DA-ergic neurons. 
Proinflammatory cytokine TNF-a synthesized predominantly by microglia and 
astrocytes is an obligatory component of DA-ergic neurodegeneration. TNF-a may link 
inflammation to apoptosis in PD.
These changes in cytokine and neurotrophin levels may be initiated by activated 
microglia, which may then promote apoptotic cell death and subsequent phagocytosis of 
DA neurons (17).
1.1.7. The role of PARP overactivation
PARP-1 is an abundant nuclear protein functioning as a DNA nick-sensor enzyme. 
Upon binding to DNA breaks, activated PARP cleaves nicotinamide adenine 
dinucleotide (NAD+) intő nicotinamide and ADP-ribose and polymerizes the latter intő 
nuclear acceptor proteins, including histones, transcription factors and PARP itself.
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Poly-(ADP-ribosylation) contributes to DNA repair and to the maintenance of genomic 
stability. Overactivation of PARP consumes NAD+ and consequently adenosine 
triphosphate (ATP), culminating in a cell dysfunction, apoptosis and necrosis. Mild 
genotoxic noxae cause PARP activation, which facilitates DNA repair and cell survival. 
Severe DNA damage, however, causes the overactivation of PARP, resulting in the 
depletionof NAD+ and ATP and consequently neuronal cell death.
Pharmacological PARP inhibition or the absence of PARP in PARP-defícient mice 
preserves cellular ATP and NAD+ pools in oxidatively stressed cells and thereby allows 
them to function normally (18).
Another role of PARP-1 is noted in the production of inflammatory mediators such as 
the iNOS (19-21), intercellular adhesion molecule-1 (ICAM-1) (22). NF-kB is a key 
transcription factor in the reguládon of this set of proteins, and PARP has been shown to 
act as a coactivator in the NF-nB-mediated transcription (23). Oxidative stress generates 
DNA single-strand breaks. DNA strand breaks then activate PARP, which in tűm 
potentiates NF-kB activation and activator protein-1 (AP-1) expression, resulting in 
greater expression of the AP-1- and NF-icB-dependent genes, such as iNOS, ICAM-1, 
macrophage inflammatory protein-la (MlP-la), TNF-a and complement 3 (C3). The 
generation of complement 5a (C5a) in combination with an increased endothelial 
expression of ICAM-1, recruits a larger number of activated leukocytesto inflammatory 
foci, producing a higher level of oxidative stress. Overactivation of PARP depletes the 
energy of the cells, which leads to the reduction of other energy- dependent molecules 
such as oxidized glutathione, the main intracellular antioxidant. As a consequence of the 
intracellular energetic failure or devastating oxidant exposure, the depletion of reduced 
glutathione induces an increased ffee radical level, resulting in greater DNA strand 
breakage.
The wide variety of animal models in which PARP inhibition has proved beneficial 
indicates that PARP inhibitors block a common pathwayof tissue injury, such as NF-kB 
activation or oxidative stress-induced cytotoxicity (24, 25).
1.2. Amyotrophic latéra! sclerosis
ALS is the most common form of degenerative MN disease in adulthood. The clinical 
picture, first described by Charcot 130 years ago, consists of generalized fasciculations,
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Progressive atrophy and weakness of the skeletal muscles, spasticity and other 
pyramidal tract signs, dysarthria, dysphagia, dyspnea and speech deficits, which are 
signs of the degeneration of the upper and lower MNs. The criteria fór the diagnosis of 
ALS, defined in Airlie House, Virginia, USA, in 1998, include clinical, 
electrophysiological, neuroradiological and pathological signs.
The disorder is often asymmetrical at its onset and the weakness typically begins 
focally. The onset of symptoms seen in ALS patients is assumed to occur when 
approximately 60-80% of MNs have been lost. It is a rapidly progressive disease, 
mostly resulting in death within 1-5 years írom onset. The prevalence of the disease 
increases with age and the male and female ratio is 1.57: 1.
There are two forms of ALS. The sporadic form (SALS) accounts fór approximately 
90% of the reported cases, while 5-10% are familial (FALS). The cause of SALS is 
unknown. Twenty per cent of the FALS cases are linked to chromosome 21 and are 
associated with mutation of the Cu/Zn (superoxide dismutase) SÓD gene. At present, 
more than 130 different mutations in the SÓD 1 gene have been reported in FALS 
patients. These mutations result in reduced Cu/Zn SÓD activity in vitro, though much 
evidence suggests a növel gain of function of the enzyme rather than a loss of function. 
The degree of reduction in its actvity does nőt correlate with either the age of onset, or 
the duration or severity of the disease.
Microglia and astrocytes are alsó involved in the pathological processes (26). Changes 
in the white matter (loss of axon myelin and fíbrillary astrocytosis) are alsó seen. The 
function of the MNs innervating the extemal ocular muscles, the striated urinary and 
anal sphincter, the abductor muscle of the larynx and the cricopharyngeal sphincter 
muscles are intact during the course of the disease.
The pathomechanisms of ALS
There are several hypotheses which account fór the degeneration of the MNs.
15
Proposcd mcchsinisniN of MN dcgcncration
PARP
Impaired 
EAAT2 Gliai
v i FreeradicateC a \
Aberrant I 
accumulation I 
of neurofilaments
Impaired axonal Overactivation of
Immuné- Excitotoxicity Oxidatíve stress transport the DNA repair
inflammatory enzyme PARP
reaction
1.2.1. The immune/inflammatory mechanism
The immune/inflammatory reaction in the CNS is characterized by activation and 
proliferation of microglia and infiltration by T cells and the presence of 
immunoglobulinG (IgG) in the MNs.
IgG antibodies directed to L-type voltage-gated Ca2+ channels were detected in the sera 
of 75% of SALS patients. ALS IgG binding to the Ca2+ channels can altér the function 
of these channels (L-type and N/P/Q channels) (27). ALS IgG was found to enhance 
Ca2+ currents in the voltage-gated Ca2+ channels in motor nerve terminals and to 
increase acetylcholine release. Accordingly, motor nerve terminals can be the site of 
immuné attack and the increase in intracellular Ca2+ may be an early event leading to 
neuronal injury.
ALS IgG passively transferred to mice induces similar ultrastructural changes in the 
MNs as observed in patients with SALS (an increased number of synaptic vesicles 
(SVs), an increased synaptic mitochondrial volume, swelling and fragmentation of the 
Golgi apparátus outer leaflet, and an increased Ca concentration in the mitochondria,
^  i
the Golgi apparátus and the endoplasmic reticulum. Furthermore, an increased Ca 
concentration and vesicle density in terminals contacting LMNs, and increased 
glutamate release from them, have alsó been observed (28). In the motor cortices of 
ALS patients, IgG was found in the pyramidal MNs. The intraperitoneal (ip) injection of 
ALS IgG results in a much greater uptake of IgG in MNs than does the injection of
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disease control IgG. Other experiments have demonstrated that the cell death mediated 
by ALS IgG is triggered by a transitory increase in íntracellular Ca2+.
Besides the presence of IgG, microglia activation has been demonstrated in the area of 
the neuronal damage. The microglia may play three possible roles: 1. phagocytosis of 
injured MNs, 2, participation in the injury, and 3, an attempt to repair the damage (29, 
30). The first and second roles have been proved; the third is only assumed in ALS.
The microglia is prominent around the UMNs and LMNs and in the degenerating 
corticospinal tracts. They play important roles as mediators of immune/inflammatory 
reactions. Around the MNs, they can proliferate and become activated. Activated 
microglia cells are competent antigen-presenting cells (31) and may play a role in the 
recognition, uptake, Processing, and presentation of antigens in the CNS. They are able 
to produce neurotoxic cytokines and free radicals (32-35), TNF-a, glutamate and iNOS.
1.2.2. Excitotoxicity
There are several lines of evidence that support the involvement of excitotoxic 
mechanisms in the pathogenesis of ALS. Glutamate is the major excitatory 
neurotransmitter in the CNS. UMNs projecting to LMNs are assumed to be 
glutamatergic, and consequently postsynaptic MNs possess a high density of glutamate 
receptors. An increased glutamate level in the synaptic cleft could induce the 
overexcitation of LMNs, leading to an excessive influx of Ca~ .
The AMPA and KA receptors are thought to be the mediators of fást excitatory 
neurotransmission. The majority of these receptors are permeable only to Na+ and K+. 
The AMPA receptors are formed from four different subunits (GluRl- GluR4). 
However, if the GluR2 is lacking, the receptors become permeable to Ca2+. A low 
expression of the GluR2 protein subunit (36) and decreased levels of the mRNA fór 
GluR2 (37) are detected in the MNs of ALS patients.
Glutamate is removed from the synaptic cleft by different uptake mechanisms. Within 
the glial cells, glutamate is either transaminated by glutamine synthetase to form 
glutamine or metabolized to a-ketoglutarate by glutamate dehydrogenase. The astrocyte 
then supplies the nerve terminál with glutamine a-ketoglutarate, or both, These are the 
precursors of the neurotransmitter glutamate. In this way, glutamate is recycled from the 
nerve terminál to the glial cells and back to the nerve terminál.
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Several EAA transporters (EAATs2) participate in the process of glutamate recycling; 
they are located on both glial and neuronal cells. Reduced levels of astroglia-specific 
EAAT2 have been reported in the motor cortex and spinal cord in the majority of ALS 
patients (38). This finding may explain the elevated glutamate level in the CSF of the 
patients. The elevated glutamate level may reflect the altered fimction of the astrocytes, 
which means that the astrocytes may alsó be involved in the pathomechanisms of 
neuronal death.
1.2.3. Oxidative stress
ROS generated during oxidative reactions can induce cellular damage through the 
oxidation of proteins, lipids and nucleic acids. If the generation of ROS exceeds the 
scavenging capacity of the cell, because of the increased ROS production or the loss of 
cellular antioxidant defense systems, oxidative stress prevails. Oxidation-induced 
damage has been demonstrated in humán SALS and FALS and in transgenic mice 
overexpressing a mutant SOD1 gene. The SOD1 enzyme gains a növel cytotoxic 
function in MN degeneration (39). One possible explanation is that the mutation affects 
the conformation of the protein and it becomes more accessible to substrates other than 
superoxide, such as hydrogen peroxide and ONOO', ffom which it generates nitronium 
ions. Nitronium ions cause the nitration of tyrosine residues and oxidatively damage 
proteins, lipids and DNA (40). Increased markers fór oxidative damage to nucleic acid 
(8-hydroxy-2’-deoxyguanosine), to proteins (carbonyl proteins) and to lipids (4- 
hydroxynonenal) have been found in FALS and SALS patients and SOD1 G93A 
transgenic mice. Neurofilaments (NFs) are further targets fór nitrosylation (41). The 
mutated SOD1 is a source of toxic ROS rather than a scavenger. Cell lines 
overexpressing a mutant SOD1 gene are known to display enhanced sensitivity to 
oxidative stress (42).
There may be a link between the oxidative stress induced by mutant SOD1 and 
glutamate-indueed cell death. Free radicals can damage the glial glutamate transporter 
(EAAT2), inducing excessive glutamatergic stimulation in consequence of the 
ínsuffícient clearance of glutamate írom the synaptic eleit. Oxidative stress leads to the 
formádon of toxic intermediates such as 4-hydroxynonenal, which impairs glutamate 
transport and induces secondary excitotoxic neurodegeneration. Another link may be
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that free radicals damage the mitochondria, resulting in a decreased production of ATP. 
The activation of PARP by DNA damage enhances this energy deficit by consuming its 
substrate, NAD+. This energy failure compromises the function of ATP-dependent ion 
pumps. The insufficient clearance of Ca2+ that enters the cell through stimulation of the 
glutamate receptors induces an increase in Ca level intracellularly, which initiates a
^ I
variety of enzymatic proccesses leading to cell death. Small vacuoles füled with Ca 
have been observed in the spinal MNs of mutant SÓD 1 G93A mice (43), and increased 
intracellular Ca2+ has been found in the motor axon terminals of patients with sporadic 
ALS (44). Finally, the formádon of protein aggregates of mutant SOD1 seems to be 
dependent on Ca2+ entry induced by glutamate stimulation, providing another link 
between these two mechanisms. The presence of very similar oxidative damage in 
FALS and SALS suggests that the mechanism of MN degeneration may involve 
oxidative stress, independently of the primary etiology. PARP-dependent microglia 
activation is known to be the source of a large amount of free radicals, damaging the 
neighboring neurons. This can be the other main source of a free radical excess in the 
tissue.
1.2.4. The role of NF accumulation in neurodegeneration
NF proteins form a major component of the neuronal cytoskeleton and have important 
functions, including the maintenance of cell shape, axonal caliber and axonal transport. 
In the perikaryon of the cells, they are composed of three subunits with different 
molecular weights (NF-heavy, NF-medium and NF-light) and are transported down the 
axon, while being phosphorylated. NF proteins are potential targets fór injury in ALS by 
nitration of their tyrosine residues. Peroxynitrite, formed fforn NO and superoxide, may 
affect NF assembly and cause NF accumulation in the MNs. NF aggregates are tightly 
linked to SOD-1 and NOS activities. Both enzymes may eontribute to peroxynitrite 
formádon at light NFs, which are rich in both tyrosine and arginine residues and hence 
regarded as the vulnerable site fór nitrotyrosine formádon. Nitrotyrosine is known to 
inhibit phosphorylation and, if it impairs the phosphorylation of NF subunits, either 
light or heavy, it may altér the slow axonal transport, culminating in the accumulation 
of NF and slowly Progressive MN death. NF accumulations in mice are accompanied by 
proximal axon swellings, an MN dysfunction, and atrophy of the skeletal muscle, bút
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these mice do nőt exhibit MN death. There is a link between excitotoxicity and aberrant 
NF accumulation, because excitoxicity can induce NF side-ann hyperphosphorylation 
and this slows NF transport in cultured neurons (45).
Free radicals alsó can induce abnormal aggregations (46). These pathomechanisms are 
strongly correlated.
1.2.5. The importance of PARP
The activation of PARP in MN degeneration may involve similar principles as in the 
degeneration of DA-ergic cells in the SN in PD: DNA damage and an elevated intra- 
motoneuronal Ca level. The later is the direct effect of autoimmune IgG directing to 
Ca2+ channels of MNs. Ca2+ promotes the activation of PARP, and Ca2+ is an activating 
factor in PARP-mediated cell killing (47, 48). Although PARP is alsó a well-known 
DNA repair enzyme, it helps cells to recover affér injury. Excessive PARP activation 
can cause the massive consumption of its substrate NAD+, with a resulting energy 
failure of the cells, which leads to cell death (49-53).
1.3. The aims of the study
This study was designed to answer the following questions:
> Does the upregulation of PARP play a role in the selective damage of MNs in ALS?
> Is the increase of PARP involved in the selective damage of the DA-ergic neurons 
of the SN in PD?
> What are the possible mechanisms of neuronal damage involving PARP 
overactivation?
> Is PARP upregulation restricted to the neurons that are damaged selectively 
alsó upregulated in other neurons?
> Is it restricted to neurons, or is it upregulated in microglial cells and astrocytes?
> How does the upregulation of PARP influence the immune-inflammatory reaction in 
neurodegenerative disease?
> What is the localization of autoimmune IgG írom ALS patients in the spinal MNs
7
affér passive transfer to mice and in the autopsy íissue írom ALS patients?
^  What is the possible role of autoimmune IgG in MN degeneration and its connection 
with PARP activation?
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j2. Materials and methods
2.1. Postmortem tissue from SALS, PD and control patients
The SALS brain (motor cortex, parietal cortex and cerebellum) and spinal cord 
specimens were obtained at autopsy from SALS patients followed in the MDA/ALS 
Clinic at the Baylor College of Medicine (n=4) and írom the University of Maryland 
Brain Bank (n=4). Postmortem samples of brains írom age-matched individuals without 
neurological diseases (n =6) and from a patient with Alzheimer’s disease (AD) were 
used as Controls. The clinical diagnoses were confírmed pathologically in all cases. 
There was no signifícant difference between the times from death to autopsy in the 
SALS and control groups (8.0 ± 2.6 h and 10.2 ± 3.5 h, respectively). Additionally, 
there was no signifícant difference between the ages at death (SALS 59.5 ± 5.0 years, 
Controls 50.3 ± 8.5 years). In the SALS group, the cause of death was respiratory failure 
(n =8). In the control group, the cause of death was a traffíc accident (3), acute drug 
poisoning, or sudden death of unknown cause (2 cases). The AD case died of hypostatic 
pneumonia.
The SN pars compacta was examined in 5 patients who had died of PD and 2 patients 
who had died of diffuse Lewy body disease (DLBD), and the results were compared 
with those on the same structure in normál (n=l), ALS (n=l), atherosclerotic (n=l) and 
AD brains (n=4). The age, gender and post mortem interval before the autopsies were 
matched. The diagnoses were established clinically and confírmed by neuropathological 
examinations.
To visualize humán IgG, approximately 6-mm pieces of the ventral horns of the 
lumbar spinal cords of 5 consecutively deceased ALS patients and 5 Controls (who had 
died from AD, PD, an ischemic stroke, a myocardial infarction, or a pulmonary 
embolism) were alsó dissected and fixed in the same fixative, with a 3-day immersion.
2.2. The preparation of IgG
Fór IgG purification, the blood was obtained by phlebotomy after ovemight fasting 
from 5 patients with clinically definite (54) and pathologically proved sporadic ALS 
and from 5 Controls (one each with AD, PD, Guillain-Barré syndrome or ischemic 
stroke, and one healthy blood donor), with their informed consent. The IgG was purified
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from the sera with AvidChrom-Protein A Kit Pure-1 according to the instructions of the 
manufacturer (Sigma Bio Sciences, Sigma Chemical Company, St Louis, MO, USA).
2.3. Animál experiments
Forty mg of pun fi ed IgG from each sample was injected ip intő 3 mice on 2 
successive days. Forty-eight h after the first injections, the animals were anesthetized 
with ketamine-xylasine (87 and 13 mg/kg, respectively), and perfused transcardially 
with phosphate-buffered physiological saline (PBS) and fixative consisting of 4% 
paraformaldehyde, 0.05% glutaraldehyde and 0.2% picric acid (55). The lumbar 
enlargements of the spinal cords and interosseous muscles from the hind limbs were 
removed and kept in the same fixative fór 3 days at 4 °C. The spinal cords were then 
chopped intő 3 mm segments and the ventral homs were dissected. The muscle samples 
from the vicinity of the terminating nerve branches were alsó dissected under a 
stereomicroscope.
Tissue samples were processed either fór immunocytochemistry, western blotting or 
electron microscopic investigations. 32 pm sections thick were cut with a vibratome and 
processed free floating in different incubation Solutions at 4 °C on a rocker to visualize 
humán IgG. After washing in PBS, the sections were preincubated with 5% normál goat 
serum in PBS fór 3 h to saturate the nonspecific IgG-binding sites. The sections were 
then incubated ovemight with a 1:200 dilution of a biotinylated affinity-purified IgG 
fraction of goat antiserum to humán IgG (heavy and light chain-specific) (Organon 
Teknika, Cappel, West Chester, PA), in 3% normál goat serum containing PBS. As a 
method control fór the immunohistochemical labeling of humán IgG, the biotinylated 
goat IgG directing to humán IgG was omitted from the process or replaced with 
unlabeled antibody. After thorough washing in PBS, the sections were divided intő two 
groups containing equal numbers of sections. One group was incubated with a 1:200 
dilution of peroxidase-conjugated avidin (Organon Teknika, Cappel, West Chester, PA) 
while the other group was incubated with a 1:200 dilution of streptavidin-ferritin 
conjugate (Bethesda Research Laboratories) fór 6 h at 4 °C. After washing in PBS, the 
sections labeled with peroxidase were exposed to 0.025% Sigma Fást™ 3,3’- 
diaminobenzidine tetrahydrochloride (DAB) (Sigma Chemical Company, St. Louis, 
MO) and 0.016% hydrogen peroxide (Fisher Scientific, Pittsburgh, PA) in PBS fór 10
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min. After washing, 10 sections of the spinal cord of each animal were pút on glass 
slides, dehydrated in series of ethanol, cleared in xylene, mounted in Permount, 
coverslipped and examined in a Nikon Optiphot light microscope.
2.4. Histological processing
2.4.1. Immunohistochemistry fór PARP
Representative sections of brains from 2 SALS patients, írom 2 normál Controls, and 
from 1 AD patient were immunostained fór PARP. Brain specimens were fixed in 10% 
neutral formaldehyde and routinely embedded in paraffin. From paraffin blocks, 
sections 5 pm in thickness were cut, deparaffinized in xylene, rehydrated in a 
descending series of ethanol, rinsed in 10 mM PBS, and then blocked fór endogenous 
peroxidase activity (0.3% H2O2 in methanol, 30 min). The sections were rinsed in PBS 
and placed in Serotec unmasking fluid (Serotec Inc., Raleigh NC) fór antigén retrieval 
in a microwave oven ( 2 x 5  min at 600 W). The sections were cooled to room 
temperature, washed in PBS, and blocked fór nonspecific IgG binding by incubation 
with 5% normál horse serum in PBS fór 30 min (Vector Laboratories, Burlingame, CA). 
Mouse monoclonal anti-human PARP antibody (Serotec US, Raleigh, NC), diluted to 
1:100 with PBS containing 2% horse serum, was applied at 4 °C, ovemight. The 
sections were rinsed in PBS and incubated with biotin-labeled horse-anti-mouse IgG 
(diluted 1:200 in PBS containing 2% normál horse serum; Vector Laboratories, 
Burlingame, CA) fór 30 min at room temperature. The sections were rinsed in PBS and 
incubated with a biotin-avidin complex conjugated to peroxidase fór 30 min (Vector 
Elité kit; Vector Laboratories, Burlingame, CA). The sections were again rinsed in PBS 
and developed using the ImmunoPure metal-enhanced DAB substrate kit fór 15 min 
(Pierce, Rockford, IL). The peroxidase reaction was terminated by extensive washing in 
distilled water. Finally, sections were dehydrated in a graded series of ethanol, cleared 
in xylene and coverslipped with Permount (Fisher Scientific, Fair Lawn, NJ). As a 
negative control, the primary antibody (mouse monoclonal anti-human PARP) was 
omitted írom the reaction or was replaced with a 1:100 dilution of normál mouse serum. 
Several sections were chosen fór double immunostaining fór both PARP and glial 
fibrillary acidic protein (GFAP) to verify that PARP-positive nuclei alsó belong to 
astrocytic cells. Fór this purpose, somé of the sections that had been stained fór PARP
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were preincubated in 5% normál goat serum fór 1 h at room temperature and then 
incubated ovemight with a 1:800 dilution of polyclonal rabbit antibody directed to 
bovine GFAP (DAKO A/S, Denmark) containing 3% normál goat serum. Affér washing 
in PBS, the sections were incubated fór 1 h in a 1:200 dilution of biotinylated anti-rabbit 
IgG at room temperature and subsequently exposed to Vector ABC Elité reagent 
(Vectors Laboratories, Inc., Burlingame, CA) fór 30 min. Affér washing, the peroxidase 
reaction was developed with the Vector VIP peroxidase substrate kit fór 5 min to 
visualize GFAP with a purple reaction product. The macrophages were identified by 
their clear cytoplasm around the nucleus affér dissolution of the phagocytized lipids 
during the process of embedding the matériái in paraffin. The sections were dehydrated, 
cleared, and coverslipped as described.
Immunostained sections were examined in a Zeiss Axioskop microscope (Kari Zeiss,
Oberkochen, equipped with a DXC-970-MD CCD camera (Sony Corp., Japan)
and a digital image analysis system (Optimas 6.2; Optimas Corp., Bothell, WA). 
Normalized PARP protein levels characterizing SALS and control groups were 
analyzed with a two-tailed Student's t-test (Excel software). Differences were 
considered statistically significant with p values of less than 0.05.
2.4.2. Immunocytochemistry fór PARP, NF-kB and parvalbumin
Deparaffinized and rehydrated sections írom the SN írom PD patients were subjected to 
immunohistochemical staining fór PARP, NF-kB (56) and parvalbumin. The detecting 
reagents were a 1:100 dilution of mouse monoclonal anti-human PARP (Serotec, 
Raleigh, NC), a 1:100 dilution of rabbit polyclonal NF-kB p65 (A) (Santa Cruz 
Biotechnology Inc., CA) and a 1:1000 dilution of mouse monoclonal anti-parvalbumin 
(Sigma Chemical Co., St. Louis, MO). Fór the whole procedure, mouse and rabbit Elité 
Vectastain ABC kits (Vector Laboratories Inc., Burlingame, CA) were used according 
to the manufacturer’s description. Consecutive sections were immunostained with the 
three antibodies, and ten sets of three sections were used fór evaluation. The sets of 
sections were cut 150 pm apart from the next set. Several other sections were double- 
stained to check on the possible co-localization of PARP with NF-kB and with 
parvalbumin. Fór this purpose, sections immunostained fór PARP and visualized with 
DAB with a metál enhancer (Sigma Chemical Co, St. Louis, MO) (brown-black color)
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were incubated secondarily with the antibody detecting parvalbumin or NF-kB. The 
second peroxidase reaction product was visualized with VIP substrate kit as a purple 
color (Vector Laboratories Inc., Burlingame, CA). The immunostained sections were 
examined in a Zeiss Axioskop microscope equipped with a DXC-970-MD CCD camera 
(Sony) and a digital image analysis system (Optimas 6.2).
2.3.3. Immunocytochemistry fór IgG
32 pm thick sections were cut with a vibratome and processed free floating in different 
incubation Solutions at 4 °C on a rocker to visualize humán IgG. After washing in PBS, 
the sections were preincubated with 5% normál goat serum in PBS fór 3 h to saturate 
the nonspecifíc IgG-binding sites. The sections were then incubated ovemight with a 
1:200 dilution of a biotinylated affinity-purified IgG fraction of goat antiserum to 
humán IgG (heavy and light chain-specific) (Organon Teknika, Cappel, West Chester, 
PA), in 3% normál goat serum containing PBS. As a method control fór the 
immunohistochemical labeling of humán IgG, the biotinylated goat IgG directing to 
humán IgG was omitted írom the process or replaced with unlabeled antibody. After 
thorough washing in PBS, the sections were divided intő two groups containing equal 
numbers of sections. One group was incubated with a 1:200 dilution of peroxidase- 
conjugated avidin (Organon Teknika, Cappel, West Chester, PA), while the other group 
was incubated with a 1:200 dilution of streptavidin-ferritin conjugate (Bethesda 
Research Laboratories) fór 6 h at 4 °C. After washing in PBS, the sections labeled with 
peroxidase were exposed to 0.025% DAB (Sigma Chemical Company, St. Louis, MO) 
and 0.016% hydrogen peroxide (Fisher Scientific, Pittsburgh, PA) in PBS fór 10 min. 
After washing, 10 sections of the spinal cord of each animal were pút on glass slides, 
dehydrated in series of ethanol, cleared in xylene, mounted in Permount, coverslipped 
and examined in a Nikon Optiphot light microscope.
2.5. Histological evaluation and statistical analysis
The sections were examined fór both the number of neurons and the percentage of 
PARP-staining neurons. All pyramidal neurons were counted in 5 randomly selected 
areas of layers III and V of the motor cortex of the SALS and control patients using a 
125x magnification. Cells with positive (dark-brown, or black) nuclear staining fór
25
PARP were counted in the same fíelds. In the parietal cortex, the large neurons were 
counted regardless of their shape. In the same area, the neurons immunostained fór 
PARP were alsó counted. In the sections of the cerebellum, the Purkinje cells were 
counted in 5 randomly selected areas; the immunostained cells were then counted as 
well. The numbers of immunostained neurons írom each individual patient were pooled 
and expressed as a percentage of the totál number of cells counted. The density of 
PARP'positive glial cells and macrophages in the subcortical white matter in the motor 
cortex, parietal cortex and cerebellum was alsó determined, using the digital image 
analysis system (Optimas 6.2; Optimas Corp., Bothell, WA). The average density of 
subcortical immunopositive cells in the motor area of the control tissues was arbitrarily 
chosen to be 100%. All of the measured densities in the subcortical white matter of the 
motor area of SALS and AD brains were compared with these values. Similarly, the 
average measured density of immunostained glial cells in the parietal and cerebellar 
subcortical white matter of the control patients was arbitrarily selected to be 100%. The 
densities of the immunostained glial cells in the parietal and cerebellar white matter of 
the SALS patients and normál Controls were expressed in comparison with this value, as 
percentages. All values fór the results of immunoblots in the Figures and the text are 
expressed as means (± standard error). The totál numbers of pigmented (neuromelanin- 
containing) neuronal cell profiles and immunostained profiles (cell nuclei fór PARP and 
NF-kB, cytoplasm fór parvalbumin) were counted in the whole cross-sections of the 
SN. As the neuronal cell content was different in the different cases (very low in PD and 
DLBD), the numbers of immunostained neurons were expressed as percentages of the 
number of all neurons containing pigment. The data were analyzed statistically with 
ANOVA (Excel software).
2.6. Western biot analysis
PARP-imunoreactivity (PARP-IR) was determined by immunobiot analysis. Samples to 
be analyzed were taken írom the frozen brain specimens by separating small pieces 
(approximately 0.5 g) írom the motor cortex, parietal cortex and cerebellum without 
thawing the tissue. Samples were homogenized with Wheatman homogenizer on ice in 
20 mM HEPES buffer (pH 7.6, containing 200 mM KC1, 2 mM EGTA, 2 mM EDTA, 
10 mM sodium molybdate, 50 mM sodium fluoride, 2 mM sodium pyrophosphate, l
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mM sodium vanadate, 0.1% NP-40, 10% glycerol, 4 mM benzamidine, 15 pg/ml 
aprotinin, 50 pM leupeptin, 1 pM pepstatin, and 1 mM phenyl-methyl-sulfonyl 
fluoride). The homogenized samples were sonicated twice with Sonic 300 
Dismembrator (Artek, Farmingdale, NY) fór 20 s. Protein content was measured by the 
Bradford method (BioRad, Hercules, CA). Each well was loaded with 100 mg of totál 
protein írom SALS and control patients. Protein samples were subjected to 8% sodium 
dodecyl sulfate polyacrylamide gél electrophoresis (SDS-PAGE) and transferred to 
nitrocellulose membranes by electroblotting. The nitrocellulose membranes were 
blocked fór 2 h at room temperature with 5% powdered milk in PBS containing 0.05%
Tween-20, then probed fór PARP using the purified mouse anti-human PARP 
monoclonal antibody 7D3-6 (Pharmingen, San Diego, CA) at a 1:1000 dilution. The 
membranes were processed by using a horseradish peroxidase-conjugated anti-mouse 
secondary antibody, and the signals were detected by using ECL chemiluminescence 
(Amersham Pharmacia, Piscataway, NJ). The reliability of sample loading and 
electroblotting in each experiment was evaluated by stripping the membranes (Reprobe,
Geno Technology Inc., St Louis, MO) and reprobing the blots with an antibody to actin 
(A4700; Sigma, St Louis, MO). Densitometric analyses were conducted with Image-J 
software (NIH image systems).
12.7. Electron microscopic techniques
Fór electron microscopic immunohistochemistry, the remaining sections (labeled with 
peroxidase or ferritin) were postfixed in 2.5% glutaraldehyde and 7.5% sucrose 
containing 0.1 M sodium phosphate buffer fór 2 h at 4 °C. They were then contrasted in
' * -Át.1% uranyl acetate fór 30 min, dehydrated in an ethanol series and embedded in Spurr nr*»t. 
(Electron Microscopy Sciences, Forth Washington, PA). Semi-thin sections (500 nm) 
were cut with an RMC-MT-7 ultramicrotome, and stained with heated 1% toluidine 
blue on glass slides. The regions of the MNs were identified under a light microscope, 
and írom these areas 70-nm thin sections were prepared. From both group of samples 
(labeled with peroxidase or with ferritin) pút on grids, every other section was 
contrasted with 7.5% magnesium uranyl acetate fór 6 min and 3% lead citrate fór 3 min.
The contrasted and noncontrasted sections were examined in a CM-12 Philips electron 
microscope. Images of interest were recorded with a Gatan camera attached to the
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electron microscope and stored in a computer fór morphometric analyses with Optimas 
software (Bioscan Inc., Edmonds, WA). Three noninjected mice were alsó examined 
with the same methods.
From each mouse (15 inoculated with ALS IgG and 15 injected with control IgG), 17- 
25 neuromuscular junctions were examined to attain a totál area of 25 pnT fór both 
peroxidase and ferritin-labeled sections at a magnification of 20000x. Fór quantification 
of the IgG content of the ATs, ferritin-labeled ultrastructural sections were used. The 
areas of the ATs were determined via the software program and all of the ferritin 
granules were counted. The densities of the granules were expressed in terms of the 
mean number of molecules/pm2 characteristic fór each animal, fór each group of 
animals that received the same IgG sample (n=3), the group of animals that received 
ALS IgG samples (n=15) and the group injected with the control IgG (n=15).
All the original numerical data were analyzed statistically with two-way repeated 
ANOVA with one between-subjects effect (the group of animals injected with ALS IgG 
versus the control group) and one within-subjects effect (densities of ferritin granules in 
axon terminals (ATs)). Ten large MNs in the ventral homs of the spinal cord of every 
mouse (approximately 400-600 pm2 area fór each) were evaluated similarly to the 
motor ATs. The areas of the rough endoplasmic reticulum (RER) were determined with 
the software program and the ferritin granules were counted and expressed as mean 
densities/pm2. The statistical evaluation was performed in the same way as above. Five 
large MNs in the ventral homs of the spinal cords of the humán samples (approximately 
3000-4000 pm2 fór each) were evaluated similarly to the mouse MNs. The areas of the 
RER were determined with the software program, while the ferritin granules were 
counted. The density of ferritin bound to molecules of humán IgG was expressed as the 
number of molecules/pm2. Two-way repeated ANOVA with one between-subjects 
effect (the group of ALS spinal eords versus the group of control spinal cords) and one 
within-subjects effect (the density of ferritin granules in the RER of individual cells) 
were used fór statistical evaluation. The amount of IgG represented by ferritin 
molecules and presumably bound to microtubules and located in the lysosomes, or in 
the multivesicular bodies in the endothelial cells, was nőt analyzed quantitatively.
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3. Results
3.1. PARP expression in different brain regions of patients with SALS (paper 1)
We have found that PARP-IR was increased in the SALS motor cortex, parietal cortex 
and cerebellum as compared with the Controls, as exemplified by a representative 
immunobiot (Fig. 1).
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FIG. 1. PARP immunoreactivity in different regions o f  ALS 
and control brains. The representative enhanced 
chemiluminescence photographs o f  immunoblots demonstrate 
increased PARP-IR in homogenates o f  the motor cortex, parietal 
cortex and cerebellum as compared with the control (Norm). 
Each well was loaded with 100 pg o f  totál protein, and blots 
were probed with anti-PARP monoclonal antibody. The 
membranes were stripped and reprobed with an anti-actin 
antibody as an internál control.
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FIG. 2. Quantitative data írom ALS and control brains.
Quantitative comparison o f  the pooled data o f  the SALS (n=8) and normál Controls 
(n=4) revealed that the PARP-IR in the motor cortex was approximately 2.5 times 
higher in the SALS than in the control brains (p=0.006). In addition, the levels o f  PARP 
in the parietal cortex and cerebellum were each about 1.6 times higher than that in the 
normál Controls (FIG. 2).
3.1.1. PARP in the motor cortex
While the normál neuronal density was preserved in the motor cortex in both the AD 
and the two normál control sections, the number of pyramidal cells was decreased in the 
SALS motor cortex, and especially the numbers of gigantocellular pyramidal cells in 
layers V and III (FIG. 3). One of the SALS patients had one-third of the number of
neurons and the second had one-quarter of the number of neurons in the control
------------ ----------  -----■ ■ 1 -------------1 ' • " * "  -  .....  ■
patients. Most of the remaining pyramidal cells in the SALS motor cortex expressed 
strong dark-brown or black nuclear staining, leaving the nucleolus unstained.
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FIG. 3. (left) PARP-positive nuclei indicated by the arrow 
in the pyramidal cells in layers III and V o f  the motor cortex 
írom an ALS patient. (right) There is no PARP staining in the 
pyramidal cells in layers III and V írom the normál control.
The scale bar is 100 pm.
The percentage of neurons immunostained and the overall intensity fór PARP in the 
ALS motor cortex were higher than in the control or AD tissue (Fig.4).
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FIG. 4. The percentage o f  PARP-positive cells was increased in the ALS sections as compared with the 
control and ALZ (Alzheimer) sections. 1 = neurons in layer III o f  the motor cortex; 2 = neurons in 
layer V o f  the motor cortex; 3 = neurons in layer III o f  the parietal cortex; 4 = neurons in layer 
V o f  the parietal cortex; 5 = Purkinje cells in the cerebellum.
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3.1.2. PARP in the parietal cortex
The parietal lobes were alsó examined. While there was no decrease in the number of 
neurons in the parietal lobé of the SALS brains, the number of PARP-immunostained 
neurons in the parietal cortex was increased relatíve to the AD and normál Controls, 
similarly to the increase seen in the motor cortex. The staining in the AD parietal 
cortical sections was similar to that in the normál Controls (Fig. 5).
FIG. 5. PARP-immunopositive neurons in the parietal cortex in a patient with 
ALS as compared with a control patient. The scale bar is 100 pm.
3.1.3. PARP in the subcortical motor region
The density and intensity of PARP-IR of glial cells in the subcortical motor area in the 
SALS sections were increased relatíve to both the AD and the normál control sections. 
The PARP-IR was increased by 515% and 482% in the two SALS samples, 100% being 
taken as the average value in the frontal subcortex of the control sections. Double 
immunostaining fór PARP and fór GFAP as well as CD68 localized the PARP 
overexpression to astrocytes and to macrophage-microglial cells. PARP-IR in the AD 
subcortical sections was similar to that fór the control sections (FIG. 6).
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FIG. 6. The dark nuclei o f  subcortical glial cells indicated by the arrow in the frontal region o f  the ALS 
brain express strong PARP immunostaining as compared with a patient with Alzheimer disease. The scale
bar is 100 pm.
3.1.4. PARP in the cerebellum
While there was no decrease in the number of Purkinje cells in the cerebellum in the 
SALS or AD, the intensity of PARP fór the two SALS sections and the AD sections was 
increased as compared with the Controls. In addition to the Purkinje cells, the cells of 
the granular layer displayed stronger immunostaining in SALS tissues than in the AD or 
normál control tissues (FIG. 7). The cerebellar granular cells írom the AD alsó 
exhibited a stronger immunostaining than that in the normál Controls.
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FIG. 7. (left) The nuclei o f  the Purkinje cells in the cerebellum o f  an ALS 
patient are strongly immunostained fór PARP. Strong immunostaining o f  
the nuclei o f  Purkinje cells fór PARP in the cerebellum o f  an AD patient.
The nuclei o f  the Purkinje cells are slightly immunostained fór PARP in a 
normál control cerebellum. (right) The nuclei o f  glial cells in the cerebellar 
white matter o f  an ALS patient express moderate immunostaining fór 
PARP. There is alsó a moderate staining in the glial cells írom an AD  
patient. The immunostaining fór PARP is lighter in the glial cells o f  the 
white matter o f  a control cerebellum. The scale bar is 100 JJ.m.
The densities of the PARP positive cerebellar glial cells in the white matter were alsó a 
little higher in the SALS tissues as compared with the control tissues (157% and 151% 
increased, 100% being the average value in the cerebellum of the control tissues). The 
subcortical cerebellar glial cells stained a little more intensely in the AD sections than in 
the normál Controls (121% increased).
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3.2. The expressions of PARP, NF-kappaB and parvalbumin in PD patients 
(paper2)
3.2.1. The expression of PARP in the SN in PD
PARP-IR was noted as a dark-gray peroxidase reaction product confmed to the nuclei of 
the neurons in the SN in PD and DLBD. Most of the neurons contained dark-brown 
particulated neuromelanin in the cytoplasm, readily distinguishable írom the PARP- 
positive nuclei by its shape and color (Fig. 8a). In the SN of samples írom PD and 
DLBD, 12.5% to 40% of the neuromelanin-containing neurons displayed PARP- 
positive nuclei (Fig. 12). Only one of the AD brains contained PARP-immunopositive 
neuronal nuclei in the SN, and only in 8% of the cells. Other control samples did nőt 
contain any PARP-immunopositive neurons in the SN (Fig. 8b).
FIG. 8. (a) Expression o f  PARP as a dark-gray peroxidase reaction product in the DA- 
ergic cells in the SN o f  a PD patient (arrow). (b) There is no PARP staining with the 
same immunohistochemical reaction in the nucleus o f  the DA-ergic cells in the SN 
írom a control sample (arrow). The scale bar is 70 pm.
The difference between the PD + DLBD group and the control group was statistically 
highly signifícant (p <0.0002). The nuclei of many of the glial cells were alsó 
immunostained positively, bút they were nőt fiirther identified as astrocytes, 
oligodendrocytes or microglial cells.
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3.2.2. The expression of parvalbumin in the SN in PD
Immunostaining fór parvalbumin revealed that 16% to 42% of the neurons in the SN of 
the patients with PD and DLBD contained cytoplasmic parvalbumin colored brown by 
the non-metal-enhanced DAB and distinct from the blue-black neuromelanin 
counterstained with hematoxylin (Fig. 9a, b).
FIG. 9. (a) Parvalbumin in the cytoplasm o f  the dopaminergic cells in the SN from a PD 
patient. One o f  the cells is indicated by arrows. There is no staining fór parvalbumin in the cells 
in the control SN (arrowhead) (b). The scale bar is 70 pm.
In the control samples, 3.2% to 14% of the neurons in the SN exhibited an 
immunopositive parvalbumin content (Fig. 12). The difference between the two groups 
was statistically significant (p <0.00004). Double immunostaining fór PARP and 
parvalbumin proved that nőne of the parvalbumin-containing neurons displayed 
increased PARP staining in the nucleus, and nőne of the PARP-immunopositive 
neurons displayed parvalbumin reactivity in their cytoplasm.
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3.2.3. The expression of NF-kB in the SN in PD
Nuclear translocation of the NF-kB were seen in the SN patients with PD and DLBD 
(FIG.lOb). The translocation of NF-kB from the cytoplasm to the nucleus occurred in 
6% to 31% of the neurons in the SN in the group of PD and DLBD. Two of the AD 
cases exhibited a similar translocation of the NF-kB in 4% and 7% of the neurons (FIG. 
12). In the other control cases, the translocation occurred in less than 1% of the cells 
(FIG. 10a). The difference between the two groups was statistically highly signifícant (p 
<0. 0006).
FIG. 10. NF-xB-positive nuclei (b) (arrow) in DA-ergic cells o f  the SN from a patient 
with PD. There is no immunoreactivity fór NF-kB in the control sample (arrowhead)
(a). The scale bar is 70 pm.
3.2.4. Colocalization of PARP and NF-kB
Consecutive sections immunostained fór PARP (Fig. 11a ) and fór NF-kB (Fig. 11b) 
proved that, in all of the neurons which exhibited translocation of NF-kB in the nucleus, 
PARP was alsó upregulated. However, the number of neurons with upregulated PARP 
was a little higher in every case than the number of cells involving the translocation of 
NF-kB.
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F IG .ll .  (a) PARP expression in the nuclei o f  DA-ergic cells in the SN írom a PD 
patient. The peroxidase reaction product is dark-gray (arrows). (b) Strong NF-kB 
immunostaining in the nuclei o f  the same cells in a consecutive section. The peroxidase 
reaction was developed with VIP substrate reagent. The scale bar is 70 pm.
50
o a o a a o a c q - J
C O i U Q - C L Q - Q - Q - —* 0  
_ l _ l <  (0Q Q <
■ PARP+
■  PA+
□  NF-kappaB+
ü a Q Q az < < < <
FIG. 12. The percentages o f  DA-ergic cells in the SN expressing 
PARP-1R (black-columns), with nuclear translocation o f  NF-kB 
(white columns) and parvalbumin-lR (striped columns). PD: 
Parkinson disease. DLBD: diffuse Lewy body disease, ALS: 
amyotrophic lateral sclerosis, AD: Alzheimer disease, ASCL: 
generalized atherosclerosis, NC: normál control.
The DA-ergic cells of the SN in DLBD and in PD patients contained significantly 
higher proportions of immunostained cells fór all three antigens than the SN írom 
control tissues. Only one AD case expressed all three antigens, bút in much lower 
proportion than the average in PD. The nuclear translocation of NF-kB staining and 
PARP-IR revealed a significant overlap in the neurons, while the immunostaining fór
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parvalbumin did nőt overlap with the cells reactive fór the previous two examined 
antigens (Fig. 12).
3.3. Appearance of humán IgG in spinal MNs of mice following ip inoculation 
(paper 3)
3.3.1. Detection of IgG in MNs
Forty-eight h afiter the initial ip injection of ALS IgG, the IgG immunoreactivity could 
be detected by the light microscopic immunohistochemical method in the perikarya of 
the spinal MNs of mice as a dense, dark peroxidase reaction product, leaving the nuclei 
unstained. All 5 ALS IgG samples gave similar reactions in all of the mice injected. The 
control samples gave much lighter uniform reactivity in the perikarya of the MNs of the 
mice injected similarly with the same dose of IgG (Fig. 13 A,B).
No peroxidase reaction product was revealed in the spinal MNs of noninjected mice 
with the same detection system. When the detecting antibody (biotinylated) was omitted 
from the reaction, no immunostaining was noted in any of the examined MNs of the 
animals.
Fig. 13. (A) The perikarya o f  MNs o f  
the ventral hóm o f  the spinal cord o f  a 
mouse injected ip with IgG from an 
ALS patient are heavily 
immunostained fór humán IgG, while 
the nuclei remain unstained. (B) The 
perikarya o f  the MNs o f  the ventral 
hóm o f  the spinal cord injected with 
IgG from a normál blood donor 
exhibit slight peripheral 
immunostaining fór humán IgG.
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3.3.2. Humán IgG detected in the RER of spinal MN of mice
FIG. 14. The RER in a spinal MN írom a mouse inoculated ip with IgG 
from an ALS patient is darkened and thickened by the reaction product 
o f  peroxidase, indicative o f  the humán IgG content (A) as compared 
withthe normál appearance o f  the RER o f  the spinal cord fforn a mouse 
injected with normál humán IgG.
The immunoreactivity of the ALS IgG was localized to the RER as precipitated 
peroxidase reaction product throughout the whole organelle. Both the membranes of the 
cistems and the ribosomes were heavily labeled in all of the examined MNs (Fig. 14A). 
The RER in the MNs of the mice injected with the control IgG samples was nőt labeled 
at all, which was indicative that little or no IgG was taken up (Fig. 14B).
The detection of humán IgG with ferritin-conjugated antibody allowed a quantitative 
comparison of the accumulation of the ALS IgG in the RER with the accumulation of 
the control IgG. In the RER of the MNs of the mice injected with the ALS IgG, the 
density of ferritin granules was 154 ± 34 (SD)/pm2 (n=50), while in the RER of the 
MNs of the mice injected with the control IgG it was 7 ± 3 (SD)/pm (n=50). The
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difference between the two groups is highly significant statistically (p < 0.0001, F = 
109.469).
3.3.3. IgG detected localized to microtubules of the MNs
Microtubules were identified as other structures labeled specifically with ferritin- 
conjugated anti-humán IgG in the perikarya and in the axons of the spinal MNs of the 
mice inoculated with the IgG írom the ALS patients. In the cell body and in the 
dendrites, groups of ferritin molecules (8-12) were noted in the vicinity of microtubules 
distributed randomly (nőt at equal distances from each other). In the peripheral axons, 
mostly single molecules were arranged in lines (Fig. 15A,B).
lOOnm
FIG. 15. (A) The ferritin-labeled 
antibody localizes IgG to a 
microtubule in the dendrité o f  a 
spinal MN (arrow) o f  a mouse 
injected ip with ALS IgG. (B) 
Humán IgG is localized by 
ferritin molecules (arrows) to the 
periphery o f  a motor axon in the 
interosseous muscle o f  a mouse 
injected ip with ALS IgG. My: 
myelin, MIT: mitochondrion
3.3.4. The detection of IgG on the external surface of a Schwann cell
At the neuromuscular junctions of the mice, the ALS IgG and the control humán IgG 
was bound heavily to the external surface of the Schwann cells as detected with
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peroxidase-labeled antibody. While the IgG írom the ALS patients seemed to induce its 
own endocytotic uptake as IgG-containing ómega formations (invaginations) írom the 
cell membráné (Fig. 16 a,b), the control IgG samples remained on the surface 
(Fig. 16 c).
FIG. 16. (a,b) IgG
labeled with the reaction 
product o f  peroxidase 
conjugated to the 
detecting antibody on 
the surface o f  a 
Schwann cell (arrows) at 
the neuromuscular 
junction o f  a mouse 
injected with ALS IgG. 
The IgG is taken up in 
vesicles displaying 
ómega formations.
(c) Normál humán IgG 
(arrow) does nőt induce 
its own uptake on the 
surface o f  the Schwann 
cell in the mouse 
injected with normál 
control IgG. Mi: 
mitochondrion. SV: 
synaptic vesicles.
3.3.5. IgG detected on the external membráné of the AT
The attachment of IgG to the external membráné of the ATs as a possible uptake site 
could nőt be visualized in any of the ATs examined. Nevertheless, the IgG from the 
ALS patients that was taken up in the motor ATs could be identified with the ferritin- 
labeled antibody. The ferritin granules were located in synaptic vesicles and attached to 
their external surface (Fig. 17A, B).
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FIG. 17. (A) IgG
detected with ferritin- 
labeled antibody in the 
motor axon terminál o f  a 
mouse injected ip with 
IgG írom an ALS 
patient (arrow). (B) The 
ferritin molecules 
localize the IgG within 
the synaptic vesicles 
(arrow), or attached 
extemally to their 
membráné.
The localization and the abundance of the ferritin granules identifying IgG in the motor 
ATs seemed to be specific fór ALS IgG, because ferritin labeling was found only 
accidentally in the ATs of the LMNs of the mice injected with the same amount of 
control IgG. In the ATs of the spinal MNs, the mean density of ferritin granules was 37 
± 3.36 (SD)/pm ), which was considerably higher than the mean density in the motor 
ATs of the mice inoculated with the control IgG (3.8 ± 2.14 (SD)/pm2). The difference 
between the two groups was highly significant statistically (p < 0.0001, F = 561.73).
3.3.6. IgG detected in the EC in mice and in patients with ALS
About two-thirds (51 of 75) of the endothelial cells (ECs) in the ventral homs of the 
spinal cords of the mice inoculated with the ALS IgG contained 2-3 multivesicular
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bodies fiiled with IgG in the cytoplasm, as detected with peroxidase or ferritin- 
conjugated antibodies (Fig. 18A). In the control IgG-injected animals, multivesicular 
bodies were observed in only about one-tenth of the endothelial cells (8 of 75). 
Ultrastructural localization of IgG in spinal MNs of ALS autopsy matériái.
In the humán autopsy matériái, the ultrastructure was severely compromised by the post 
mortem autolysis.
FIG. 18. (A) The peroxidase 
reaction product labels humán 
IgG in multivesicular bodies 
(arrows) in the endothelial cell 
(EC) in the ventral hóm o f  the 
spinal cord o f  a mouse injected 
ip with ALS IgG.
(B) IgG Iabeled with ferritin- 
conjugated antibody is taken 
up in an EC in the ventral hóm  
o f  the spinal cord o f  a patient 
who died írom ALS. The 
ultrastructure is severely 
compromised by the
postmortem autolysis, bút the 
IgG can be localized to a 
multivesicular body (thick
arrow). The thin arrow
indicates IgG molecules 
attached to the surface o f  the 
cell. My: myelin; N: nucleus; 
EC: endothelial cell
One or two multivesicular bodies füled with IgG were detected with ferritin- Iabeled 
antibody in almost one-third (9 of 30) of the examined ECs in the ventral homs of the 
ALS spinal cords (Fig. 18B), bút nőne in the control tissues. There were traces of IgG 
on the surface of the ECs in tissues írom the ALS cases and írom the Controls.
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3.3.7. IgG detected in proximity to microtubules and in the RER in patients with 
ALS
IgG could be detected with ferritin-labeled antibody in the spinal MNs of the ALS 
patients. Ferritin molecules were localized to the RER in large groups (containing 30-50 
molecules) and to the microtubules in smaller groups (6-14 molecules).
FIG. 19. In spite o f  the severely compromised ultrastructure, the IgG can be localized to the RER 
(left arrow) and to the microtubules (Mt) (right arrow).
The density of the ferritin molecules was calculated to be 271 ±43 (SD)/pm2 (n=25) in 
the RER in the spinal MNs of the ALS samples and 9 ± 4 (SD)/pm2 (n=25) in the RER 
of the control tissues. The difference between the two groups was highly significant 
statistically (p < 0.0001, F = 1053.45).
The interactions were nőt significant in the data obtained írom the groups (MNs of 
mice: p = 0.205, F = 1.754; ATs in mice: F = 0.839, p = 0.45; MNs in humán spinal 
cords:F= 1.655, p = 0.185).
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4. Discussion
In the UMNs, there is an overactivation of PARP. This overactivation could lead to the 
excessive consumption of NAD+ and the depletion of internál energy sources, further 
aggravating the ATP deficit (57) of the UMNs. The resulting energy failure could 
jeopardize the function of the ATP-requiring ionic pumps which maintain the 
electrochemical gradients across neuronal plasma membranes, leading to apoptosis (58) 
and/or necrosis (59) of the UMNs. Clearly, we can State that PARP overactivation may 
be responsible fór the death of the UMNs in ALS. Thus, with respect to PARP-IR, the 
spinal MNs appear to behave in an opposite way to the pyramidal neurons, because 
there is an increase in the PARP level in the UMNs, and a decrease in the LMNs (60, 
61). A potential explanation is that the spinal MNs may have evolved mechanisms to 
prioritize other highly ATP-dependent processes, such as ubiquitination and 
proteosomal removal of aggregated proteins (62), decreasing the intracellular Ca level, 
enhancing the altered axoplasmic transport (63) and preserving neurotransmitter release 
írom an increased number of sprouted axon terminals in ALS. The death of the LMNs 
may occur because of the functional deficiency of the enzyme fór repair of the injured 
DNA. Further studies are required to explain the differences in PARP reactivity in the 
UMNs and LMNs. This type of abnormal activation of PARP has been implicated 
earlier in the development of cell damage in MPTP-induced PD (64), AD (65), ischemic 
brain damage (66) and CNS trauma (67).
The increased expression of PARP-IR was nőt confmed to the motor cortex in ALS 
patients, bút was alsó increased in the neurons of the parietal and cerebellar cortices, 
(though on less extensively) areas, which are nőt known to be involved in ALS 
pathogenesis.
The slight overactivation of PARP in other than motor areas may reflect the situation 
that oxidative stress is widespread in the ALS brain. As only MNs die selectively in 
ALS, we presume that the PARP overactivation only in these cells exceeds the 
threshold of being irreversibly damaging.
The significant increase in PARP expression in the nuclei of a subset of DA-ergic 
neurons in the SN in PD and DLBD may be a consequence of both oxidative damage 
and an increased intracellular Ca level leading to apoptosis. PARP is required as 
coactivator fór the nuclear translocation and transcriptional activation of NF-kB in DA-
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ergic neurons. NF-kB has been implicated in the regulation of genes involved in many 
processes, including apoptosis. The molecular mechanism fór the damage of the DA- 
ergic neurons in the SN in PD may be the transcriptional activation of oncogene p53, 
inducing programmed cell death (68, 69). The relevance of this mechanism in PD has 
been questioned by others (70) because NF-kB is protective in other neuronal cell types 
(71) and alsó in PC 12 cells (72). The nuclear translocation of NF-kB was noted in cells 
which alsó expressed an increased PARP level, as evidenced by the immunostaining of 
consecutive sections fór the two different antigens. The data support the view that NF- 
kB promotes apoptosis (73), because PARP can alsó serve as a marker fór the onset of 
programmed cell death (74).
Besides the MNs, PARP is alsó increased in the microglia cells and astrocytes. PARP is 
necessary fór the activation of microglia and macrophages. Following activation, the 
microglia and macrophages release ffee radicals (75, 76), which could damage the cell 
membráné of neighboring neurons and the astroglial glutamate transporter. Microglia 
can alsó enhance neuronal injury by releasing the cytokines IL-ip, IL-2, IL-6, IL-10, , 
TNF-a, IFN-y (76, 78), iNOS, COX-2, glutamate (77), all of which could lead to a 
raised intracellular Ca2+ level in the neurons, increased neuronal ffee radicals and 
subsequent DNA damage and PARP activation. The soluble constituents released írom 
the microglia could alsó diffuse widely from their release sites. This can be the 
explanation why other than MNs express increased PARP in ALS.
PARP-IR is alsó increased in the astrocytes. Since the astroglia may be an important 
source of antioxidant protection (79-81) and releases neurotrophic factors, the increased 
PARP-IR in the astrocytes indicates a somewhat compromised ability to mediate critical 
neuroprotective functions (82, 83).
PARP-IR is alsó increased in the neurons in the parietal and cerebellar cortices, areas 
which are nőt known to be involved in ALS pathogenesis. This means that in ALS there 
is a widespread oxidative stress in the CNS. The fact that parietal neurons express 
increased PARP in ALS, yet do nőt degenerate, could be a reflection of their increased 
resistance to the toxic effects of the “stressor(s).” If, as proposed, oxidative stress is the 
major “stressor”, then increased intracellular Ca2+ could result írom the increased 
oxidative stress. The relatíve resistance of the parietal cells could relate to their ability 
to buffer the increased Ca2+ load due to the ample presence of the Ca2+-binding proteins
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calbindinD28K and/or parvalbumin. Furthermore, non-MNs, such as parietal lobé 
neurons, may well have more efficient antioxidant capacities than MNs. The Purkinje 
cells in the cerebellum appeared to be partially protected from PARP increases, possibly 
because of their well-known high concentrations of the Ca2+-binding proteins 
calbindinD28k and/or parvalbumin (84).
Increased oxidative stress (85-94) provides a potential explanation as the generál cause 
of the neuron damage, bút the source of such enhanced oxidative stress is unknown. The 
presence of widespread microgliosis is a potential clue. Altematively, the enhanced 
microgliosis could be a response to increased oxidative stress. However, our present 
data cannot differentiate oxidative stress that initiates microglial activation from 
oxidative stress that results from microglial activation. As microglia activation is 
dependent on PARP activation, and the microglia regulates the local immune- 
inflammatory response, the inhibition of PARP can decrease the immune/inflammatory 
processes. Meanwhile, the PARP inhibitors in neurons ean savé the cells from 
unnecessary energy depletion.
Furthermore, the increased number of astrocytes containing high amounts of PARP 
mainly in the motor cortex suggests that cells other than neurons may be subjected to 
pathologic stressors in ALS, and in tűm, such altered glia may contribute to the 
pathogenesis of ALS.
Nevertheless, it is clear that the increased PARP-IR is nőt confmed to the motor system, 
bút is increased throughout many regions of the CNS of ALS patients, with the relatíve 
neuronal damage mediated by selective mechanisms of vulnerability and resistance. 
There is evidence that in SALS immune/inflammatory mechanisms are involved in the 
pathomechanisms of the disease. The anti-MN IgG is part of this process.
The effects of ALS IgG on the neurons vary under different experimental conditions, 
from cell destruction in cultures (95, 96), to the initiation of degeneration in vivő (97) 
and the increase of neurotransmitter release in vivő (28, 98) and in vitro (99). The 
changes seem to be mediated by the increase in the level of intracellular Ca2+ (100). The 
increase in intracellular Ca2+ is due to the effect of ALS IgG on the Ca2+ channels (101) 
and is promoted by Fcy receptors (102). In our experiments, however, IgG bound to the 
extemal membráné of the motor Ats, where the Ca2+ channels are located, was nőt 
detected. One possible reason is the rapid uptake of IgG in the terminál. Nevertheless,
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the demonstrated action of ALS IgG on the Ca2+ channels does nőt exclude the 
possibility that other subpopulations of IgG molecules exert their effects elsewhere in 
the cell.
The accumulation of IgG in the RER might interfere with the synthesis of proteins 
essential fór the normál fiinctioning of the MNs or induce an elevation of cytosolic Ca2+ 
due to release from the internál Stores (103). However, the enrichment of IgG in the 
RER may alsó be fully secondary, due to a humorai immuné response to the continuous 
release of antigens from previously destroyed MNs. They can be taken up passively by 
the intemalization of synaptic vési cl es from the plasma membráné of the ATs and fmd 
their antigén target intracellularly.
IgG bound to the microtubules in the cells may be of greater importance in inducing a 
cell dysfunction. Modifications of the proteins of the microtubules in ALS precede 
detectable ultrastructural changes in the axons (104). The microtubules determine the 
location and organization of the Golgi apparátus within the cells. Monoclonal antibodies 
directing to tubulin, a microtubule protein, lead to a dramatic dispersal of the Golgi 
apparátus when microinjected intő cells (105). The ffagmented neuronal Golgi is 
functional in ALS and in mice with the G93A mutation of the Cu/Zn SÓD gene caused 
by the disruption of the microtubules (106). The signifícance of the alterations in the 
microtubules and fást axonal transport in inducing MN disease has been proved in 
Drosophila (107). Microtubules and NFs are linked by frequent crossbridges in situ 
(108), and the altered fást axonal transport can therefore compromise the slow transport 
too. The finding that ALS IgG is bound to microtubules in passive transfer experiments 
on mice and alsó in ALS tissue, and the above literature data demonstrating the 
signifícance of the dysfunction of the microtubules in MN disease, warrant further 
experimental work.
As ip administered ALS IgG raises the glutamate level in the CSF in rats, i.e. it acts on 
and can be detected in synaptic boutons residing on LMNs (109), it is envisaged that 
IgG accesses neurons írom the extracellular space in the CNS. There is no proof of an 
overall disturbance of the blood-brain barrier functions in ALS, bút our experiment 
yielded morphological evidence of the translocation or at least the uptake of IgG 
through CNS ECs in the affected areas of the spinal cord in ALS. There may be 
multiple antibodies targeting a variety of epitopes of MNs in ALS. Somé of them have
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been proved to be relevant in causing functional abnormalities, and even cell death in 
different cell cultures. IgG passively transferred írom the sera of ALS patients to mice 
may be cytotoxic (110), or at least initiate the degeneration of MNs with ultrastructural 
alterations similar to those in the preliminary stages of apoptosis. The harmful effects of 
antibodies directed to antigens in the RER or bound to microtubules have yet to be 
proved.
The accumulation of IgG in MNs may serve only as signaling fór the microglia and 
locally regulate the expression of complement receptors on it. Although the recruitment 
of microglial cells may be beneficial in to removing foreign materials, the sustained 
activity of these cells may have detrimental effects on the neurons (111).
The signs of chronic activation of the microglia and astrocytes occur in selected areas 
of damage in the CNS of patients with neurodegenerative disease such as SALS and 
PD.
In the passive transfer experiments, activated CDI lb-positive microglial cells were 
demonstrated in the ventral hóm of mouse spinal cords after the ip injection of IgG írom 
SALS patients or írom guinea pigs with experimental autoimmune gray matter disease. 
The latter is induced by the immunization of guinea pigs with the homogenate of the 
ventral hóm of bovine spinal cord. The activated microglial cells can damage the 
neurons by releasing cytotoxic cytokines, excitatory neurotransmitters and ROS. 
Reactive microglia alsó releases the highly toxic peroxynitrite molecules, which inhibit 
the function of membráné proteins such as glutamate transporters located on the surface 
of the astrocytes, and in this way, they contribute to elevated glutamate levels and 
enhance excitotoxicity. The activated microglia may alsó have neuroprotective effects.
It is known that microglial-derived IL-1 is required fór the astrocytic production of 
ciliary neurotrophic factors and insulin-like growth factor 1, both of which help repair 
the damaged CNS. Thus, they can altér the phagocytic properties of the microglia and 
potentiate the engulimént of dying cells (112). From this point of view, the intracellular 
IgG is implicated in the local inflammatory process characteristic of ALS. As regards a 
low antibody level directed to certain MN antigens in the blood of ALS patients, as 
opposed to this, the enrichment, the undetermined length of stay and the effects of these 
multiple IgGs inside the MNs may contribute to the failure of immunosuppressive 
treatment (insufficient and too laté) in ALS.
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In vitro, the IgG of ALS patients binds to L-, N and P-type Ca2+ channels and enhances 
Ca2+ influx intő cultured MNs (27). The increased intracellular Ca2+ activates PARP, 
which plays the already discussed important role in neuron degeneration. The enhanced 
PARP-IR could reflect enhanced activation of the DNA repair systems in response to 
widespread oxidative damage.
Oxidative stress (113), excitotoxicity (102) and immune/inflammatory (114, 115) 
processes act in concert in the pathomechanism of neurodegenerative diseases such as 
ALS and PD.
The common pathway of excitotoxicity, oxidative stress and inflammation involves 
increased level of intracellular Ca2+ in the damaged neurons. Our data indicate that the 
level of parvalbumin detected by immunohistochemistry is increased in the injured 
neurons in the SN in PD. We consider this to be an indirect sign of an increased 
intracellular Ca2+ level. There is no way to detect the in vivő Ca2+ content of the cells in 
autopsy matériái, because the post mortem autolysis influences the Ca2+ compartments 
in the cells. An increased parvalbumin level apparently helps the cell buffer an 
increased intracellular Ca2+ level. Nőne of these neurons expressed an increased PARP 
level or the nuclear translocation of NF-kB as signs of an apoptotic process. It seems 
that a certain proportion of the neurons in the SN pars compacta upregulate parvalbumin 
in response to an increased intracellular Ca level and, at least temporarily, are then 
protected írom cell death, similarly to the neurons of the pars reticulata of the SN (116). 
The role of such an increase level of parvalbumin in protecting the MNs from death has 
been proved under experimental conditions (117, 118). The cells with increased PARP 
expression did nőt display a simultaneously increased parvalbumin immunoreactivity in 
their cytoplasm; hence, they are nőt protected by this Ca2+-buffering mechanism. 
However, most of those cells exhibit simultaneous nuclear translocation of NF-kB 
colocalized with PARP and undergo apoptosis.
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The new fmdings presented in this work are as follows:
> PARP is upregulated in the motor cortex of ALS patients; this is detected at a f 
protein level by immunoblotting.
> PARP upregulation is primarily localized to the pyramidal cells undergoing t 
degeneration by immunohistochemistry in the motor cortex.
> A milder increase in PARP was noted in other neurons, which usually do nőt 
degenerate in ALS.
> A PARP increase was alsó noted in the DA-ergic neurons of the SN in PD.
In PD, PARP overactivation coactivates NF-kB, which is a transcription factor fór 
p53 gene expression inducing apoptosis.
^  Increased PARP in the microglia reflects its activation, which seems to be necessary 
to release neurotoxic substances.
> PARP is upregulated in astrocytes, altering their protective function on neurons.
> Autoimmune IgG írom ALS targets MNs and is taken up in them. Ultrastructurally, 
it is bound to the AT of the neuromuscular junction, transported by microtubules to 
the cell body and accumulated in the RER and in the Golgi apparátus. IgG increases 
intracellular Ca2+, which alsó activates PARP.
> In ALS patients, the IgG is localized in the same ultrastructures as in the MNs of 
mice after passive transfer via ip injection.
> PARP overactivation in the neurons can damage the cells in a cell-autonomous 
manner and alsó by activation of the microglia.
> PARP overactivation seems to be a common pathway in the mechanisms of 
selective neurodegeneration in ALS and PD.
> PARP inhibitors are of potential benefit in the treatment of both diseases.
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